Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040352 · ClinicalTrials.gov registry record
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
A clinical trial of Melanoma and Dysplastic Nevus Syndrome, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 2
- Study locations
NCT00040352 is a study of Melanoma and Dysplastic Nevus Syndrome that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 3,000 participants, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT00040352, a study of Melanoma and Dysplastic Nevus Syndrome, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions. Individuals \>=4 weeks with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participants will: * Fill out one or two questionnaires about their personal and family medical history. * Provide written consent for researchers to review their medical records and pathology materials related to their care and those of deceased relatives with melanomas, tumors, cancer, or other related illnesses for whom they are the next-of-kin or legally authorized representative. * Donate a blood or cheek cell sample to be used for genetic studies. (The blood sample is collected through a needle in an arm vein. The cheek cell sample is obtained either by gently brushing the inside of the mouth with a soft brush or by swishing a tablespoon of mouthwash and then spitting it into a container.) * Undergo a skin biopsy (removal of a small piece of skin tissue) for genetic study. For this procedure, the area of skin to be removed is numbed with a local anesthetic and a 1/4-inch piece of skin is excised with a cookie cutter-like instrument. The wound is then covered with a band-aid. Participants may be asked to travel to the NIH Clinical Center for evaluation, including a medical history, physical examination, and some of the following procedures: * Full body skin examination to evaluate the type and number of moles and document any evidence of sun damage to the skin. The examination involves all the skin from the scalp to the bottoms of the feet. After the examination, a medical photographer will photograph the skin, with close-ups of skin lesions marked by the examiner. If there are parts of the skin the participant does not want examined or photographed, he or she can tell the examiner. * Blood draw of about 120 milliliters (4 ounces) or less * Skin biopsy * Cheek cell sample
Conditions Studied
Study Locations (2)
Maryland
- National Cancer Institute (NCI) - Bethesda
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2002-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040352
The ClinicalTrials.gov registry entry for NCT00040352 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT00040352 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00040352 about?
NCT00040352 is a clinical study titled "Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma". This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions. Individuals \>=4 weeks with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participa...
What is the current status of trial NCT00040352?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2002-07-01.
What conditions does trial NCT00040352 study?
This clinical trial studies the following conditions: Melanoma, Dysplastic Nevus Syndrome.
Who is sponsoring clinical trial NCT00040352?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00040352 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.